Carotid intima-media thickness in heavily pretreated HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 5, 2003, Pages 490-493

  Chironi, Gilles ^a   Escaut, Lelia ^b   Gariepy, Jerome ^a   Cogny, Anne ^c   Monsuez, Jean Jacques ^b   Levenson, Jaime ^a   Simon, Alain ^a   Vittecoq, Daniel ^b  

^a HÔPITAL BROUSSAIS   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Antiretroviral therapy; Carotid arterie; HIV; Intima media thickness; Risk factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; LIPID;

ADULT; ANAMNESIS; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BODY COMPOSITION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE PREDISPOSITION; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOLIPOPROTEINEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; BLOOD; BODY MASS; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; INTIMA; MIDDLE AGED; RISK FACTOR;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; TUNICA INTIMA;

EID: 0037446454     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304150-00004     Document Type: Article

References (19)

1. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1- protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-1883.
2. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of protease inhibitors [letter]. Lancet. 1998;351: 1959.
3. Engstrom JW, Lowenstein DH, Bredesen DE. Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome. Am J Med. 1989;86:528-532.
4. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.
5. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intimamedia thickness and risk of stroke and myocardial infarction. The Rotterdam Study. Circulation. 1997;96:1432-1437.
6. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
7. Gariepy J, Salomon J, Denarie N, et al. Sex and topographic differences in associations between large-artery wall thickness and coronary risk profile in a French working cohort: the AXA Study. Arterioscler Thromb Vasc Biol. 1998;18:584-590.
8. Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481-1492.
9. Tieftz NW. Fundamentals of clinical chemistry. Philadelphia: WB Saunders, 1982:477-479.
10. 2). Clin Chem. 1983;29:2025-2029.
11. Neeley WE. Simple automated determination of serum or plasma glucose by a hexokinase-glucose-6-phosphate dehydrogenase method. Clin Chem. 1972;18:509-15.
12. Graf S, Gariepy J, Massoneau M, et al. Experimental and clinical validation of arterial diameter waveform and intima media thickness obtained from B-mode ultrasound image processing. Ultrasound Med Biol. 1999;25:1353-1363.
13. Simon A, Gariepy J, Moyse D, et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 2001;103:2949-2954.
14. Simon A, Gariepy J, Chironi G, et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002;20:159-169.
15. Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992;2:23-28.
16. Castelli WP. The new pathophysiology of coronary artery disease. Am J Cardiol. 1998;82:60T-65T.
17. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
18. Lamarche B, Despres JP, Pouliot MC, et al. Metabolic heterogeneity associated with high plasma triglyceride or low HDL cholesterol levels in men. Arterioscler Thromb. 1993;13:33-40.
19. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.